The study by Khan et al. examines the association between circulating interleukin-6 (IL-6) levels and cardiovascular (CVD) events in a diverse cohort of healthy adults from the Multi-Ethnic Study of Atherosclerosis (MESA). The primary objective was to investigate the relationship between IL-6 levels and CVD outcomes across different racial and ethnic groups. The study included 6,622 participants with a median follow-up of 14 years. IL-6 levels were divided into three terciles, with higher levels associated with increased risks of all-cause mortality, CV mortality, non-CV mortality, and heart failure (HF). The adjusted hazard ratios (HRs) for these outcomes were 1.98, 1.55, 2.05, and 1.48, respectively, for the highest IL-6 tercile compared to the lowest. When tested as continuous variables, higher IL-6 levels were consistently associated with increased risks of all outcomes. The findings were consistent across all racial and ethnic groups, with no significant differences in the risk of outcomes between non-Hispanic White (NH White) and other racial/ethnic groups. The study highlights the prognostic role of IL-6 in CVD and suggests that targeting IL-6 may be a potential therapeutic strategy to reduce CVD risk in diverse populations.The study by Khan et al. examines the association between circulating interleukin-6 (IL-6) levels and cardiovascular (CVD) events in a diverse cohort of healthy adults from the Multi-Ethnic Study of Atherosclerosis (MESA). The primary objective was to investigate the relationship between IL-6 levels and CVD outcomes across different racial and ethnic groups. The study included 6,622 participants with a median follow-up of 14 years. IL-6 levels were divided into three terciles, with higher levels associated with increased risks of all-cause mortality, CV mortality, non-CV mortality, and heart failure (HF). The adjusted hazard ratios (HRs) for these outcomes were 1.98, 1.55, 2.05, and 1.48, respectively, for the highest IL-6 tercile compared to the lowest. When tested as continuous variables, higher IL-6 levels were consistently associated with increased risks of all outcomes. The findings were consistent across all racial and ethnic groups, with no significant differences in the risk of outcomes between non-Hispanic White (NH White) and other racial/ethnic groups. The study highlights the prognostic role of IL-6 in CVD and suggests that targeting IL-6 may be a potential therapeutic strategy to reduce CVD risk in diverse populations.